IL-27 Antibody is affinity chromatography purified via peptide column.
Immunogen
Anti-IL-27 antibody was raised against a peptide corresponding to 14 amino acids near the center of human IL-27. The immunogen is located within amino acids 80 - 130 of IL-27.
IL27
Reaktivität: Human
ELISA, FACS
Wirt: Maus
Monoclonal
B-G49
unconjugated
Applikationshinweise
WB: 2-4 μ,g/mL.
Antibody validated: Western Blot in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
IL-27 Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
IL-27 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
IL-27 (IL27)
(Interleukin 27 (IL27))
Andere Bezeichnung
IL-27
Hintergrund
IL-27 Antibody: Like interleukin-23 (IL-23), IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. It exists as a heterodimer composed of the p40-related protein EBI3 and an IL-12 p35-related protein termed p28. IL-27 is produced after activation by antigen-presenting cells and induces proliferation of naive but not memory CD4+ T-cells. It acts by binding to its receptor WSX-1 and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting the IL-27 is involved in the regulation of immune processes. It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet.